Biologic activity of a dinuclear Pd(II)-spermine complex toward human breast cancer

Chemical Biology and Drug Design

Volumn 77, Issue 6, 2011, Pages 477-488

  Fiuza, Sónia M ^a   Holy, Jon ^b   Batista de Carvalho, Luis A E ^a   Marques, Maria P M ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Gamma H2AX; Human breast cancer; Pd(II) complex; Polynuclear; Spermine; Wortmannin

Indexed keywords

CISPLATIN; DNA; ESTROGEN RECEPTOR; HISTONE H2AX; PALLADIUM COMPLEX; PALLADIUM SPERMINE COMPLEX; SPERMINE; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 79955949585     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01081.x     Document Type: Article

References (60)

1. World Health Organization (2008) Mortality Profiles. Geneva: WHO.
2. Bastos J., Barros H., Lunet N. (2007) Evolução da mortalidade por cancro da mama em Portugal (1955-2002). Acta Med Port;20:139-144.
3. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. (1969) Platinum compounds: a new class of potent antitumor agents. Nature;222:385-386.
4. Nielsen T.O., Hsu, F.D, Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T. et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res;10:5367-5374.
5. Galanski M., Arion V.B., Jakupec M.A., Keppler B.K. (2003) Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des;9:2078-2089.
6. Zeizinger M., Burda J.V., Sponer J., Kapsa V., Leszczynski J. (2001) A systematic ab initio study of the hydration of selected palladium square-planar complexes. A comparison with platinum analogues. J Phys Chem A;105:8086-8092.
7. Burda J.V., Zeizinger M., Leszczynski J. (2004) Activation barriers and rate constants for hydration of platinum and palladium square-planar complexes: an ab initio study. J Chem Phys;120:1253-1262.
8. Ray S., Mohan R., Singh J.K., Samantaray M.K., Shaikh M.M., Panda D., Ghosh P. (2007) Anticancer and Antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. J Am Chem Soc;129:15042-15053.
9. Kuduk-Jaworska J., Puszko A., Kubiak M., Pełczynska M. (2004) Synthesis, structural, physico-chemical and biological properties of new palladium (II) complexes with 2, 6-dimethyl-4-nitropyridine. J Inorg Biochem;98:1447-1456.
10. Mansuri-Torshizi H., Ghadimy S., Akbarzadeh N. (2001) Synthesis, characterization, DNA binding and cytotoxic studies of platinum(II) and palladium(II) complexes of the 2, 2'-bipyridine and an anion of 1, 1-cyclobutanedicarboxylic acid. Chem Pharmacol Bull;49:1517-1520.
11. Fiuza S.M., Amado A.M., Oliveira P.J., Sardão V.A., Batista de Carvalho L.A.E., Marques M.P.M. (2006) Pt(II) vs Pd(II) polyamine complexes as new anticancer drugs: a structure-activity study. Lett Drug Des Discov;3:149-151.
12. Budzisz E., Krajewska U., Rozalski M. (2004) Cytotoxic and proapoptotic effects of new Pd(II) and Pt(II)-complexes with 2-ethanimidoyl-2-methoxy-2H-1, 2-benzoxaphosphinin-4-ol-2-oxide. Pol J Pharmacol;56:473-478.
13. Butour L., Wimmer Wimmer F., Castan P. (1997) Palladium(II) compounds with potential antitumour properties and their platinum analogues: a comparative study of the reaction of some orotic derivatives with DNA in vitro. Chem Biol Interact;104:165-178.
14. Wheate N.J., Collins J.G. (2003) Multi-nuclear platinum complexes as anti-cancer drugs. Coord Chem Rev;241:133-145.
15. Teixeira L.J., Seabra M., Reis E., Girao da Cruz M.T., Pedroso de Lima M.C., Pereira E., Miranda M.A., Marques M.P.M. (2004) Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates. J Med Chem;47:2917-2925.
16. Marques M.P.M., Girao T., De Lima M.C.P., Gameiro A., Pereira E., Garcia P. (2002) Cytotoxic effects of metal complexes of biogenic polyamines. I. Platinum(II) spermidine compounds: prediction of their antitumour activity. Biochim Biophys Acta;1589:63-70.
17. Jodrell D.I., Evans T.R.J., Steward W., Cameron D., Prendiville J., Aschele C., Noberasco C., Lind M., Carmichael J., Dobbs N., Camboni G., Gatti B., De Braud F. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur J Cancer;40:1872-1877.
18. Qu Y., Scarsdale N.J., Tran M.-C., Farrell N. (2004) Comparison of structural effects in 1, 4 DNA-DNA interstrand cross-links formed by dinuclear and trinuclear platinum complexes. J Inorg Biochem;98:1585-1590.
19. Marverti G., Andrews P.A., Piccini G., Ghiaroni S., Barbieri D., Moruzzi M.S. (1997) Modulation of cis-diamminedichloroplatinum(II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur J Cancer;33:669-675.
20. Codina G., Caubet A., López C., Moreno V., Molins E. (1999) Palladium(II) and Platinum(II) Polyamine Complexes: X-Ray Crystal Structures of (SP-4-2)-Chloro{N-[(3-amino-kN)-propyl]propane-1, 3-diamine-kN, kN'}palladium(1+)Tetrachloropalladate(2-)(2:1) and (R, S)-Tetrachloro[n-(spermine)dipalladium(II) (= {N, N'-Bis[(3-amino-kN)-propyl]butane-1, 4-diamine-kN:kN'}tetrachlorodipalladium). Helv Chim Acta;82:1025-1037.
21. Gurel V., Sens D.A., Somji S., Garrett S.H., Nath J., Sens M.A. (2003) Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat;80:181-191.
22. Keepers Y.P., Pizao P.E., Peters G.J., van Ark-Otte J., Winograd B., Pinedo H.M. (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer;27:897-900.
23. 2O) and its metal coordination complexes; pitfalls in the use of the MTT-assay. J Exp Clin Cancer Res;24:63-68.
24. Fricker S.P., Buckley R.G. (1996) Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res;16:3755-3760.
25. Papazisis K.T., Geromichalos G.D., Dimitriadis K.A., Kortsaris A.H. (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods;208:151-158.
26. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. (1990) New colorimetric cytotoxic assay for anticancer-drug screening. J Natl Cancer Inst;82:1107-1112.
27. Boulton S., Kyle S., Yalintepe L., Durkacz B.W. (1996) Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells. Carcinogenesis;17:2285-2290.
28. Berenbaum M.C. (1992) Correspondence re: W. R. Greco et al., Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Res; 50:5318-5327, 1990. Cancer Res;52:4558-4560.
29. Christodoulopoulos G., Muller C., Salles B., Kazmi R., Panasci L. (1998) Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res;58:1789-1792.
30. Kartalou M., Essigmann J.M. (2001) Recognition of cisplatin adducts by cellular proteins. Mut Res;478:1-21.
31. Roos W.P., Kaina B. (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med;12:440-450.
32. Tercero J.M., Matilla A., Sanjuan M.A., Moreno C.F., Martin J.D., Walmsley J.A. (2003) Synthesis, characterization, solution equilibria and DNA binding of some mixed-ligand palladium(II) complexes. Thermodynamic models for carboplatin drug and analogous compounds. Inorg Chim Acta;342:77-87.
33. Quiroga A.G., Perez J.M., Montero E.I., Masaguer J.R., Alonso C., Navarro-Ranninger C. (1998) Palladated and platinated complexes derived from phenylacetaldehyde thiosemicarbazone with cytotoxic activity in cis-DDP resistant tumor cells. Formation of DNA interstrand cross-links by these complexes. J Inorg Biochem;70:117-123.
34. Rothkamm K., Kruger I., Thompson L.H., Lobrich M. (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol;23:5706-5715.
35. Powis G., Bonjouklian R., Berggren M.M., Gallegos A., Abraham R., Ashendel C., Zalkow L., Matter W.F., Dodge J., Grindey G., Vlahos C.J. (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res;54:2419-2423.
36. Schultz L.B., Chehab N.H., Malikzay A., Halazonetis T.D. (2000) p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J Cell Biol;151:1381-1390.
37. Boulton S., Kyle S., Durkacz B.W. (2000) Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur J Cancer;36:535-541.
38. Losada R., Riveroa M.T., Slijepcevic P., Goyanes V., Fernandez J.L. (2005) Effect of wortmannin on the repair profiles of DNA double-strand breaks in the whole genome and in interstitial telomeric sequences of Chinese hamster cells. Mut Res;570:119-128.
39. Pavon M.A., Parreno M., Leon X., Sancho F.J., Cespedes M.V., Casanova I., Lopez-Pousa A., Mangues M.A., Quer M., Barnadas A., Mangues R. (2008) Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. Int J Cancer;123:1068-1079.
40. Haber J.E. (2000) Partners and pathways repairing a double-strand break. Trends Genet;16:259-264.
41. Crul M., van Waardenburg R.C.A.M., Bocxe S., van Eijndhoven M.A.J., Pluim D., Beijnen J.H., Schellens J.H.M. (2003) DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol;65:275-282.
42. Martin L.P., Hamilton T.C., Schilder R.J. (2008) Platinum resistance: the role of DNA repair pathways. Mol Path;14:1291-1295.
43. Pawelczak K.S., Andrews B.J., Turchi J.J. (2005) Differential activation of DNA-PK based on DNA strand orientation and sequence bias. Nucleic Acids Res;33:152-161.
44. Lees-Miller S.P., Meek K. (2003) Repair of DNA double strand breaks by non-homologous end joining. Biochimie;85:1161-1173.
45. Dip R., Naegeli H. (2005) More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit. FASEB J;19:704-715.
46. Frankenberg-Schwager M., Garg I., Gregus A., Neumann C., Penningers H., Pralle E., Frankenberg D.S. (2006) Wortmannin, an inhibitor of DNA double-strand break rejoining, sensitizes human cells to radiation but protects against the cytotoxic effect of cisplatin: relevance for radiochemotherapy? Radiother Oncol;78:S50.
47. Siddik Z.H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene;22:7265-7279.
48. Koehn H., Magan N., Isaacs R.J., Stowel K.M. (2007) Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs;18:419-425.
49. Raaphorst G.P., Li L.F., Yang D.P. (2006) Evaluation of adaptative responses to cisplatin in normal and mutant cell lines with mutations in recombination repair pathways. Anticancer Res;26:1183-1187.
50. Chirnomas D., Taniguchi T., de la Vega M., Vaidya A.P., Vasserman M., Hartman A.-R., Kennedy R., Foster R., Mahoney J., Seiden M.V., D'Andrea A.D. (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther;5:952-961.
51. Andreassen P.R., D'Andrea A.D., Taniguchi T. (2004) ATR couples FANCD2 monoubiquitination to the DNA-damage response. Gen Dev;18:1958-1963.
52. Jacome A., Navarro S., Casado J.A., Rio P., Madero L., Estella J., Sevilla J., Badell I., Ortega J.J., Olivé T., Hanenberg H., Segovia J.C., Bueren J.A. (2006) A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in Fanconi anemia patients. Hum Gene Ther;17:1-6.
53. Jensen R., Glazer P.M. (2004) Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci;101:6134-6139.
54. Kruszewski M., Bouzyk E., Oldak T., Samochocka K., Fuks L., Lewandowski W., Fokt I., Priebe W. (2003) Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3, 4-diamine-2, 3, 4, 6-tetradeoxy-a-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratog Carcinog Mutagen;23:1-11.
55. McHugh P.J., Spanswick V.J., Hartley J.A. (2001) Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol;2:483-490.
56. Brabec V., Kasparkova J., Vrana O., Novakova O., Cox J.W., Qu Y., Farrell N. (1999) DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochem;38:6781-6790.
57. Jia J., Zhu F., Ma X., Cao Z.W., Li Y.X., Chen Y.Z. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov;8:111-128.
58. Tulub A.A., Stefanov V.E. (2001) Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol;28:191-198.
59. Zeidan Y.H., Jenkins R.W., Hannun Y.A. (2008) Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol;181:335-350.
60. Kopf-Maier P., Muhlhausen S.K. (1992) Changes in the cytoskeleton pattern of tumor cells by cispaltin in vitro. Chem Biol Interact;82:295-316.